ArticleJournal of pain and symptom management2025
Palliative Care Program Characteristics and End-of-Life Outcomes for Patients With Metastatic Cancer.
Article in Journal of pain and symptom management, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
contextAlthough U.S. palliative care programs have substantial differences in their implementation, whether this heterogeneity impacts patient outcomes is unknown.
objectivesTo determine if palliative care program characteristics are associated with differences in end-of-life quality metrics for patients with metastatic cancer.
methodsRetrospective cohort study of patients with metastatic cancer who received care from programs that participated in the National Palliative Care Registry, 2018-2019. Multilevel regression was used to examine the association between individual program characteristics and outcomes including use of hospice, hospice enrollment ≥ 3 days, use of intensive care (ICU) in the last 30 days of life, and use of chemotherapy in the last 14 days of life.
resultsThe cohort was comprised of 33,015 patients who received care from 235 palliative care programs. Program maturity was the only characteristic associated with a difference in any outcome. Patients who received care from mature programs were more likely to use hospice (adjusted hazard ratio (aHR) 1.15 [1.06-1.25], for 5-10 years vs. < 5 years; aHR 1.18 [1.09-1.29] for > 10 years vs. < 5 years), and were also more likely to have hospice enrollment ≥ 3 days (aHR 1.18 [1.08-1.31] for 5-10 years vs. < 5 years; aHR 1.22 [1.11-1.34] for > 10 years vs.< 5 years).
conclusionPalliative care program characteristics largely were not associated with differences in end-of-life quality metrics for patients with metastatic cancer. Further work is needed to better understand why program maturity may be associated with improved outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.